Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
to assess the efficacy and safety of recombinant human interferon α-2b gel (Yallaferon®) for
the treatment of patients with cervical high-risk HPV infections; to analyze the HPV type
infections and clinical negative conversion.
285 patients with positive high risk HPV infection were randomized into interferon gel group
and control group at ratio of 2:1 (203 patients in treatment group and 82 patients in control
group). The patients in treatment group received 1g recombinant human α-2b interferon gel
every other day for consecutive 3 courses of treatment, whereas no treatment was conducted in
control group.